Verallia SAS (0ABH)
London Exchange · UK · prices in EUR · close of 15 Oct 2026
Key indicators
| Last close | EUR 18.43 |
|---|---|
| 52-week range | 15.46 – 24.38 |
| Return, 1 month / 3 months | −0.2% / −8.7% |
| Return, 1 year / 3 years | −13.0% / −37.2% |
| Trend | Below its 200-day average |
| RSI (14) | 56 |
| Volatility (1 year) | 30.8% |
| Worst drawdown (1 year) | -34.6% |
| Average daily value traded | 0.02M EUR |
| Dividend yield | 5.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Verallia is a glass packaging company based in France that makes bottles and jars for drinks, food and other consumer products. Its customers include producers of wine, spirits, beer, soft drinks and food, who rely on the company for container glass in various shapes, colours and sizes. Verallia operates glass furnaces and production plants serving markets in Europe and beyond, supplying packaging for everyday branded and private-label goods.
On this site Verallia SAS appears as a stock on the London Exchange (UK), code 0ABH, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Verallia SAS (0ABH) trades on the London Exchange in UK. It last closed at EUR 18.43 on 15 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 2,740 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.0% and over the last three months it fell 8.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.8% | ||
| From 52-week high | -24.1% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.7% | ||
| 6-month return | 0.4% | ||
| 12-month return, skipping the last month | -12.8% | ||
| Stability (higher is calmer) | 50 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.6% | ||
| Liquidity | 17 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 5.4% | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | −0.2% |
| 3 months | −8.7% |
| 6 months | +0.4% |
| 1 year | −13.0% |
| 3 years | −37.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 18.39 / 19.16 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 May 2026 | EUR 1.0000 |
| 13 May 2025 | EUR 1.7000 |
| 14 May 2024 | EUR 2.1500 |
| 8 May 2023 | EUR 1.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.